Anlotinib plus pemetrexed as a further treatment for patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study.
Jueming Chen(Guangzhou First People's Hospital), Yanna Zhang(China Electronics Technology Group Corporation), Xingyu Jiang(Sun Yat-sen University), Jiaqi Qiu(Sun Yat-sen University), Ting Wan(Guangzhou University of Chinese Medicine), Libing Song(Sun Yat-sen University), Lie Zheng(Sun Yat-sen University), He Huang(Renmin University of China), Wei Wei(Zhujiang Hospital), Jihong Liu(Sun Yat-sen University), Han Li(Anhui Polytechnic University), Min Zheng(Second Affiliated Hospital of Zhejiang University), Ying Xiong(Sichuan University), Yanling Feng(First Affiliated Hospital of Guangzhou Medical University), Jundong Li(University of Virginia)
Cited by 2
Related Papers
Feature Selection
|ACM Computing Surveys|2017|2.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice
|Cell|2024|253
Line Graph Neural Networks for Link Prediction
|IEEE Transactions on Pattern Analysis and Machine Intelligence|2021|235
Wnt5a induces and maintains prostate cancer cells dormancy in bone
|The Journal of Experimental Medicine|2018|223